2000-2019年美国丙型肝炎相关住院的时间趋势
分析2000-2019年全国住院患者样本中成人丙型肝炎相关住院趋势。估计共1 286 397例次住院,年龄调整住院率2019年最低(18.7/10万)而2012年最高(29.6/10万)。2013年后住院率持续下降,与直接抗病毒药物上市时间重合,但不同年龄、种族/民族和保险类别间下降不均。
要点
- 2000-2019年美国估计有1 286 397例次HCV相关住院。
- 年龄调整住院率2019年最低(18.7/10万),2012年最高(29.6/10万)。
- 2013-2019年年龄调整住院率年变化百分比为-7.6%(P<.001)。
核心结论
- 尽管多种因素可能起作用,2013年后HCV相关住院率总体稳步下降,与DAA上市时间重合。
- 下降在年龄、种族/民族或保险类别间并不均等。
- 需要扩大DAA治疗可及性,尤其在Medicaid和Medicare受益人中,以减少差异和疾病负担并消除丙型肝炎的公共卫生威胁。
研究设计与样本
- 分析2000-2019年全国住院患者样本中≥18岁成人的数据。
- HCV相关住院定义为:丙型肝炎为主要诊断,或丙型肝炎为任何次要诊断且主要诊断为肝脏相关疾病。
主要发现
- 2000-2019年估计有1 286 397例次HCV相关住院。
- 年龄调整住院率2019年最低(18.7/10万),2012年最高(29.6/10万)。
- 多数住院发生于45-64岁(71.8%)、男性(67.1%)、白人非西班牙裔(60.5%)和Medicaid/Medicare受益人(64.0%)。
- 全国年龄调整住院率在2000-2003年上升(APC 9.4%;P<.001),2003-2013年上升(APC 1.8%;P<.001),2013-2019年下降(APC -7.6%;P<.001)。
- 与2000年相比,2019年住院率增幅最大的是55-64岁人群(132.9%)、Medicaid受益人(41.6%)和黑人非西班牙裔(22.3%)。
临床怎么用
- 作者认为需要扩大DAA治疗可及性,尤其在Medicaid和Medicare受益人中,以减少差异和疾病负担并消除丙型肝炎的公共卫生威胁。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hospitalization burden related to hepatitis C virus (HCV) infection is substantial. We sought to describe temporal trends in hospitalization rates before and after release of direct-acting antiviral (DAA) agents. METHODS: We analyzed 2000-2019 data from adults aged ≥18 years in the National Inpatient Sample. Hospitalizations were HCV-related if (1) hepatitis C was the primary diagnosis, or (2) hepatitis C was any secondary diagnosis with a liver-related primary diagnosis. We analyzed characteristics of HCV-related hospitalizations nationally and examined trends in age-adjusted hospitalization rates. RESULTS: During 2000-2019, there were an estimated 1 286 397 HCV-related hospitalizations in the United States. The annual age-adjusted hospitalization rate was lowest in 2019 (18.7/100 000 population) and highest in 2012 (29.6/100 000 population). Most hospitalizations occurred among persons aged 45-64 years (71.8%), males (67.1%), White non-Hispanic persons (60.5%), and Medicaid/Medicare recipients (64.0%). The national age-adjusted hospitalization rate increased during 2000-2003 (annual percentage change [APC], 9.4%; P < .001) and 2003-2013 (APC, 1.8%; P < .001) before decreasing during 2013-2019 (APC, -7.6%; P < .001). Comparing 2000 to 2019, the largest increases in hospitalization rates occurred among persons aged 55-64 years (132.9%), Medicaid recipients (41.6%), and Black non-Hispanic persons (22.3%). CONCLUSIONS: Although multiple factors likely contributed, overall HCV-related hospitalization rates declined steadily after 2013, coinciding with the release of DAAs. However, the declines were not observed equally among age, race/ethnicity, or insurance categories. Expanded access to DAA treatment is needed, particularly among Medicaid and Medicare recipients, to reduce disparities and morbidity and eliminate hepatitis C as a public health threat.
引用
- Hofmeister MG, Zhong Y, Moorman AC, et al. Temporal Trends in Hepatitis C-Related Hospitalizations, United States, 2000-2019. Clin Infect Dis. 2023. PMID: 37463305. doi:10.1093/cid/ciad425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。